CAMP4 Therapeutics Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 22.43K shares, a 83.98% increase year-over-year.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 1.70K shares.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 1.00 shares.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 24.13K shares, a 95.30% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 513.78K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 22.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 24.13K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 1.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 13.89K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | |
| 2025-03-31 | 1.00 shares 10-Q · filed 2025-05-13 | |
| 2024-12-31 | 12.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 513.78K shares 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |